"T cell population expansion in response to allogeneic cancer vaccine alone (DPV-001) or with granulocyte-macrophage colony-stimulating factor (GM-CSF) or imiquimod (I) for definitively-treated stage III NSCLC patients (pts)." by Bernard A. Fox

Selected Works of Walter J. Urba, MD, PhD

Article

T cell population expansion in response to allogeneic cancer vaccine alone (DPV-001) or with granulocyte-macrophage colony-stimulating factor (GM-CSF) or imiquimod (I) for definitively-treated stage III NSCLC patients (pts).

Journal of Clinical Oncology (2017)

Bernard A. Fox, Oregon Health & Science University
Brian C. Boulmay, LSU Health Sciences Center New Orleans
Rui Li, Providence Portland Medical Center
Kyle T Happel
Christopher Paustian, Cleveland Clinic
Tarsem Lal Moudgil, Providence Portland Medical Center
Sachin Puri, Providence Portland Medical Center
Christopher Dubay, Oregon Health & Science University
Yoshinobu Koguchi, Providence Portland Medical Center
Adi Mehta
Fridtjof Lund-Johansen, University of Oslo
Brenda K Fisher, Providence Portland Medical Center
William L Redmond, Providence Portland Medical Center
Carlo Bruno Bifulco, University of Milan
Augusto Ochoa, Science Applications International Corporation
Hong-Ming Hu, Providence Portland Medical Center
Traci Hilton
Walter John Urba
Rachel E. Sanborn, Providence Portland Medical Center

Disciplines

Publication Date

May 30, 2017

Citation Information

Bernard A. Fox, Brian C. Boulmay, Rui Li, Kyle T Happel, et al.. "T cell population expansion in response to allogeneic cancer vaccine alone (DPV-001) or with granulocyte-macrophage colony-stimulating factor (GM-CSF) or imiquimod (I) for definitively-treated stage III NSCLC patients (pts)." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/walter-urba/94/